drugset
drugset / Trial / NCT04596007

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets in Chinses Healthy Subjects

NCT04596007 ↗

Phase 1 Completed 74 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC83518 Tablets in Chinses Healthy Subjects

Timeline

Start
2020-04-01
Primary completion
2020-09-10
Completion
2020-09-10

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC83518 Unknown 5 mg —
Subject HEC83518 Unknown 10 mg —
Subject HEC83518 Unknown 20 mg —
Subject HEC83518 Unknown 40 mg —
Subject HEC83518 Unknown 80 mg —
Subject HEC83518 Unknown 140 mg —
Subject HEC83518 Unknown 200 mg —

Indications

insomnia